Minerva Neurosciences Inc (NERV)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.30-4.17%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Minerva Neurosciences Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.16
Annual ending 2026-12-31
Revenue	—	19.76M
EPS	—	-2.52
Annual ending 2027-12-31
Revenue	—	56.49M
EPS	—	-0.68

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain $200 million equity offering program	It has a $200 million equity program to fund operations.	Intact	Equity program is reduced or unavailable before 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Limit operating losses and cash burn	The company aims to control losses while advancing its drug.	Broken	Operating loss exceeds negative $16.7 million in 2026-Q1	Operating income: $-10.642M FY2026-Q2; GAAP. Published target: Operating loss no worse than negative $16.7 million in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 7, 2026-10,642,159 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ba6fc22b-28a9-494a-8065-286cd453364a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete Phase 3 trial enrolling 380 patients	Minerva is running a key Phase 3 trial with 380 patients.	Intact	Trial enrollment falls short of 380 patients by 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. R&D expenses increased from $5.3 million in 2026-Q1 to $7.2 million in 2026-Q2, reflecting investment in the C19 Phase 3 trial. Management remains focused on execution with topline efficacy data expected in 2H 2027, indicating delivery aligned with stated plans. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 3
2026-07-25	Unavailable	Unavailable	1 / 3
2026-07-26	Unavailable	Unavailable	1 / 3
2026-07-27	Unavailable	Unavailable	1 / 3
2026-07-28	Unavailable	Unavailable	1 / 3
2026-07-29	Unavailable	Unavailable	1 / 3
2026-07-30	Unavailable	Unavailable	2 / 3
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	1 / 3
2026-08-02	Unavailable	Unavailable	1 / 3
2026-08-03	Unavailable	Unavailable	1 / 3
2026-08-04	Unavailable	Unavailable	1 / 3
2026-08-05	Unavailable	Unavailable	1 / 3
2026-08-06	Unavailable	Unavailable	1 / 3
2026-08-07	Unavailable	Unavailable	1 / 3
2026-08-08	Unavailable	Unavailable	2 / 3
2026-08-09	Unavailable	Unavailable	2 / 3
2026-08-10	Unavailable	Unavailable	1 / 3
2026-08-12	Unavailable	Unavailable	1 / 3
2026-08-13	Unavailable	Unavailable	1 / 3
2026-08-14	Unavailable	Unavailable	1 / 3
2026-08-15	Unavailable	Unavailable	1 / 3
2026-08-16	Unavailable	Unavailable	1 / 3
2026-08-17	Unavailable	Unavailable	1 / 3
2026-08-18	Unavailable	Unavailable	1 / 3
2026-08-19	Unavailable	Unavailable	1 / 3
2026-08-20	Unavailable	Unavailable	1 / 3
2026-08-21	Unavailable	Unavailable	1 / 3
2026-08-22	Unavailable	Unavailable	1 / 3
2026-08-23	Unavailable	Unavailable	1 / 3
2026-08-24	Unavailable	Unavailable	1 / 3
2026-08-25	Unavailable	Unavailable	1 / 3
2026-08-26	Unavailable	Unavailable	1 / 3
2026-08-27	Unavailable	Unavailable	1 / 3
2026-08-28	Unavailable	Unavailable	1 / 3
2026-08-29	Unavailable	Unavailable	1 / 3
2026-08-30	Unavailable	Unavailable	1 / 3
2026-08-31	Unavailable	Unavailable	1 / 3
2026-09-01	Unavailable	Unavailable	1 / 3
2026-09-02	Unavailable	Unavailable	1 / 3
2026-09-03	Unavailable	Unavailable	1 / 3
2026-09-04	Unavailable	Unavailable	1 / 3
2026-09-05	Unavailable	Unavailable	1 / 3
2026-09-06	Unavailable	Unavailable	1 / 3
2026-09-07	Unavailable	Unavailable	1 / 3
2026-09-08	Unavailable	Unavailable	1 / 3
2026-09-09	Unavailable	Unavailable	1 / 3
2026-09-10	Unavailable	Unavailable	1 / 3
2026-09-11	Unavailable	Unavailable	1 / 3
2026-09-12	Unavailable	Unavailable	1 / 3
2026-09-13	Unavailable	Unavailable	1 / 3
2026-09-14	Unavailable	Unavailable	1 / 3
2026-09-15	Unavailable	Unavailable	1 / 3
2026-09-16	Unavailable	Unavailable	1 / 3
2026-09-17	Unavailable	Unavailable	1 / 3
2026-09-18	Unavailable	Unavailable	1 / 3
2026-09-19	Unavailable	Unavailable	1 / 3
2026-09-20	Unavailable	Unavailable	1 / 3
2026-09-21	Unavailable	Unavailable	1 / 3
2026-09-22	Unavailable	Unavailable	1 / 3
2026-09-23	Unavailable	Unavailable	1 / 3
2026-09-24	Unavailable	Unavailable	1 / 3
2026-09-25	Unavailable	Unavailable	1 / 3
2026-09-26	Unavailable	Unavailable	1 / 3
2026-09-27	Unavailable	Unavailable	1 / 3
2026-09-28	Unavailable	Unavailable	1 / 3
2026-09-29	Unavailable	Unavailable	1 / 3
2026-09-30	Unavailable	Unavailable	1 / 3
2026-10-01	Unavailable	Unavailable	1 / 3
2026-10-02	Unavailable	Unavailable	1 / 3
2026-10-03	Unavailable	Unavailable	1 / 3
2026-10-04	Unavailable	Unavailable	1 / 3
2026-10-05	Unavailable	Unavailable	1 / 3
2026-10-06	Unavailable	Unavailable	1 / 3
2026-10-07	Unavailable	Unavailable	1 / 3
2026-10-08	Unavailable	Unavailable	1 / 3
2026-10-09	Unavailable	Unavailable	1 / 3
2026-10-10	Unavailable	Unavailable	1 / 3
2026-10-11	Unavailable	Unavailable	1 / 3
2026-10-12	Unavailable	Unavailable	1 / 3
2026-10-13	Unavailable	Unavailable	1 / 3
2026-10-14	Unavailable	Unavailable	1 / 3
2026-10-15	Unavailable	Unavailable	1 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	1 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	1	2
2026-06-01	1	2
2026-07-01	1	2
2026-08-01	2	2
2026-09-01	2	1
2026-10-01	2	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain $200 million equity offering programDirect metric needs a verified mapping
Limit operating losses and cash burnPublished status: Broken
Complete Phase 3 trial enrolling 380 patientsDirect metric needs a verified mapping

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.3%Typical daily move · historical

Downside history

-71.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Minerva Neurosciences Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making clinical-stage company, not an established earnings compounder. The long-term thesis is in a watch state: the Phase 3 program is progressing, but recent financial performance is weak and near-term execution risk is elevated.

What's priced into Minerva Neurosciences Inc

The evidence snapshot provides no valuation or market-expectations data, so whether NERV looks cheap or expensive versus peers cannot be assessed. Recent performance has lagged its industry cohort, and the thesis has not freshly broken, but the evidence does not show what expectations are already reflected.

What the fundamentals likely do

Near term, consecutive earnings misses leave an elevated risk of another miss, while cash has declined and liabilities have increased. Management says the Phase 3 confirmatory trial for roluperidone remains on track, with topline efficacy data expected in the second half of 2027; R&D spending rose as trial investment increased. Financing and leadership transitions remain areas to monitor.

What Minerva Neurosciences Inc hinges on

The multi-year view hinges on completing the Phase 3 trial and producing the expected efficacy data, alongside the company’s ability to manage its capital needs. A guidance cut or further earnings weakness would add pressure, while continued strength among healthcare sector bellwethers could support the sector backdrop. The jobs trend is another risk factor in the evidence, though its specific effect on NERV is uncertain.